Masonic Cancer Center at University of Minnesota

Site:	Masonic Cancer Center at University of Minnesota	Go to their website
Address:
City:	Minneapolis
State:	MN
Zip:	55455
Country:	USA

Phase	Trial	Trial Status	Site Status	Drug	NCT#
2	A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors	Terminated	Closed	Olaratumab (IMC-3G3)	NCT01316263
1	Cixutumumab and Temsirolimus in Treating Young Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	Suspended	Closed	IMC-A12 + CCI-779	NCT00880282
3	A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)	Recruiting	Active	Ripretinib	NCT05734105
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
2	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	Active, not recruiting	Closed	Entrectinib	NCT02568267